Tr1 cells for use in atherosclerosis
CA 2575689 C · Owner: Institut National De La Sante Et De La Recherche Medicale (Inserm) · Inventors: Mallat, Ziad; Groux, Herve; Brun, Valerie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal and b) the TO cell population , activated by said antigen said TO cell population being obtained from a CD4+ T lymphocyte population of said mammal.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 11, 2004 and granted April 2, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 11, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 11, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.